FindTrial
Sign In

Difference in awkaening time of cisatracurium-related paralysis with different doses of neostigmine

Comparative study of different methods of administration of neostigmine to reduce the reversal time of cisatracurium-induced moderate neuromuscular blockade.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/055639
Enrollment
72
Registered
2023-07-25
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K402- Bilateral inguinal hernia, withoutobstruction or gangrene

Interventions

Intervention1: neostigmine 60 mcg: Neostigmine 60mcg/kg with glycopyrolate 20 mcg/kg when the TOFc will be 3 and 0.9% saline when the TOFr will be 0.4 Intervention2: Neostigmine(60) and glycopyrolate(

Sponsors

ANSHU KUMARI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA Physical status of I or II Duration of surgery - 60 mins upto 120 mins.

Exclusion criteria

Exclusion criteria: 1.Refusal to participate in the study 2.Presence of kidney, liver or neuromuscular disease 3.Contraindication to the use of any of the drugs used in the study 4.Body mass index (BMI) >30 kg m-2 5.Viral marker status positive/ COVID 6.Pregnant patient

Design outcomes

Primary

MeasureTime frame
To evaluate the time required for the reversal of moderate blockade using neostigmine 60 mcg / kg or for reversal of superficial blockade using neostigmine 30 mcg / kgTimepoint: Time of appearance of 1.TOFc 3 2.TOFr 0.4 3.TOFr0.1—

Secondary

MeasureTime frame
Adverse effects related to neostigmine and glycopyrolate in the post operative periodTimepoint: upto 2hrs postoperatively.—

Countries

India

Contacts

Public ContactAnshu kumari

IGIMS,PATNA

kumarianshu20@gmail.com9693466864

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026